Alefacept in corticosteroid refractory graft versus host disease: early results indicate promising activity.

Steroid refractory graft versus host disease (GVHD) presents a significant therapeutic challenge due to the limited efficacy and safety of second-line treatments. Three patients with extensively pretreated, refractory GVHD were treated with a targeted anti-T-cell agent, alefacept, and demonstrated rapid and clinically significant improvement in their GVHD, facilitating tapering of corticosteroids. The pathological and immunohistochemical findings of GVHD also improved, validating our clinical impression. These preliminary findings indicate that alefacept may have beneficial activity in GVHD warranting further study.
AuthorsAmir A Toor, Patrick J Stiff, Brian J Nickoloff, Tulio Rodriguez, Jared L Klein, Kenneth B Gordon
JournalThe Journal of dermatological treatment (J Dermatolog Treat) Vol. 18 Issue 1 Pg. 13-8 ( 2007) ISSN: 0954-6634 [Print] England
PMID17365261 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Validation Study)
Chemical References
  • Adrenal Cortex Hormones
  • CD2 Antigens
  • Dermatologic Agents
  • Recombinant Fusion Proteins
  • Alefacept
  • Adrenal Cortex Hormones (pharmacology)
  • Adult
  • Aged
  • Alefacept
  • Bone Marrow Transplantation
  • CD2 Antigens (metabolism)
  • Dermatologic Agents (therapeutic use)
  • Female
  • Graft vs Host Disease (drug therapy)
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell (therapy)
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive (therapy)
  • Lymphoma, Non-Hodgkin (therapy)
  • Male
  • Middle Aged
  • Recombinant Fusion Proteins (therapeutic use)
  • T-Lymphocytes (drug effects)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!

Choose Username:
Verify Password:
Enter Code Shown: